Integrated Diagnostics Holdings (FRA:8I8) Moat Score: 0/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8I8 Integrated Diagnostics Holdings PLC FRA:8I8
65 GF Score
Price €0.41
GF Value €0.45
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Integrated Diagnostics Holdings Moat Score?

Integrated Diagnostics Holdings has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Integrated Diagnostics Holdings has Narrow Moat: Integrated Diagnostics Holdings has a solid narrow moat due to its strong brand in the diagnostics sector and significant market share in the MENA region. The company benefits from economies of scale and a robust distribution network, but lacks significant global presence and network effects to warrant a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Integrated Diagnostics Holdings might have No Moat - No discernible moat.

Integrated Diagnostics Holdings  (FRA:8I8) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Integrated Diagnostics Holdings Moat Score Related Terms

FRA:8I8
65GF Score
Integrated Diagnostics Holdings PLC FRA:8I8
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Integrated Diagnostics Holdings (FRA:8I8) Overvalued in 2026?

Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued. The current stock price of €0.41 is trading 8% below its estimated GF Value™ of €0.45. GuruFocus considers Integrated Diagnostics Holdings to be Fairly Valued.

Key valuation signals for FRA:8I8:

  • Moat Score: 0
  • GF Value™: €0.45 vs. price of €0.41 (8% below fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the FRA:8I8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integrated Diagnostics Holdings Business Description

Other Exchanges IDGXF:USAIDHCl:UKIDHC:UK
Address 12 Castle Street, St Helier, JEY, JE2 3RT
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
65GF Score

Get the complete analysis for FRA:8I8

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.41
Price
€0.45
GF Value